Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of lenvatinib in relapsed or refractory pediatric solid malignancies
2019-004441-33Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in Non-hematologic malignancy and glioma (2 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at Week 16. Started Apr 2020; status: active.
02
Drugs
lenvatinib
03
Conditions
Non-hematologic malignancyglioma
Beyond the preview
Go deeper on 2019-004441-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004441-33.